Form 4: AngioDynamics CEO James Clemmer Acquires Shares Through Performance Share Unit Vesting

AngioDynamics CEO James C. Clemmer acquired 56,279 shares of common stock through the vesting of performance share units and disposed of 28,730 shares to cover tax obligations.

Summary

• On July 17, 2024, James C. Clemmer, the President and CEO of AngioDynamics Inc., acquired 56,279 shares of common stock due to the vesting and settlement of performance share units granted on July 21, 2021.
• He also disposed of 28,730 shares to satisfy tax withholding obligations related to the vesting of these performance share units.
• Following these transactions, Clemmer directly owns 661,582 shares of AngioDynamics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects routine transactions related to executive compensation. The acquisition of shares through vesting is mildly positive, while the sale for tax obligations is neutral.

Positives

• The vesting of performance share units indicates that performance metrics were met, which could be seen as a positive signal.

Negatives

• The sale of 28,730 shares to cover tax obligations, while routine, could be perceived negatively if investors are highly sensitive to insider selling.

Risks

• The document does not explicitly mention any risks.
• However, investor sentiment could be affected by insider transactions, even if they are routine.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership. It is common for executives to receive stock-based compensation and to sell shares to cover tax obligations.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects the CEO's compensation and ownership stake in the company.
• Employees may view the vesting of performance shares as a positive sign of company performance.

Key Dates